Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

Carde, Patrice; Hagenbeek, Anton; Hayat, M.; Monconduit, M.; Thomas, José; Burgers, Melanie C J; Noordijk, Evert M.; Tanguy, Alain; Meerwaldt, J.H.; Fur, R. Le

doi:10.1200/jco.1993.11.11.2258

Cited by 189 publications

(63 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Presence of B symptoms, stage at presentation, and age were strong prognostic markers (P ϭ .03, P ϭ .002, and P ϭ .0001 respectively), consistent with previous studies. 10,42,43 However, because of our selection procedure as described above, the number of patients with advanced-stage and recurrent HD entered in this study were higher than expected from those studies.…”

Section: Patient Characteristicscontrasting

confidence: 48%

High numbers of active caspase 3–positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome

Dukers

Meijer

Berge

et al. 2002

Blood

View full text Add to dashboard Cite

In vitro studies suggest that resistance to the apoptosis-inducing effect of chemotherapy might explain poor responses to therapy in fatal instances of Hodgkin disease (HD). Execution of apoptosis depends on proper functioning of effector caspases, in particular caspase 3, which is activated on the induction of apoptosis through either the stress-induced pathway or the death receptor-mediated pathway. Thus, high levels of caspase 3 activation should reflect proper functioning of one or both identified apoptosis pathways, resulting in chemotherapy-sensitive neoplastic cells and thus a favorable clinical response to chemotherapy. We

show abstract

Section: Patient Characteristicscontrasting

confidence: 48%

High numbers of active caspase 3–positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome

Dukers

Meijer

Berge

et al. 2002

Blood

View full text Add to dashboard Cite

show abstract

“…Owing to the increasing use of combination chemotherapy at early stages, the result of the H6-F study of the EORTC, use of prognostic factors and improved CT and MRI techniques, staging laparotomy has disappeared as a routine staging procedure (Glatstein et al, 1969;Carde et al, 1993).…”

Section: Discussionmentioning

confidence: 99%

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

et al. 2004

View full text Add to dashboard Cite

“…All male patients with early stage classical Hodgkin's lymphoma included in the EORTC-GELA intergroup trials H6, H7, H8 and H9 (1982-2004) [10][11][12][13] were analyzed. Patients were aged 15 to 70 years and presented with histologically proven, previously untreated, clinical stage I or II supradiaphragmatic Hodgkin's lymphoma with World Health Organization (WHO) performance status grade 0-2.…”

Section: Patientsmentioning

confidence: 99%

Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials

Kaaij¹,

Heutte²,

Echten-Arends³

et al. 2009

Haematologica

View full text Add to dashboard Cite

BackgroundAlthough widely recommended, cryopreservation of sperm is sometimes not performed for patients with Hodgkin's lymphoma because of presumed poor sperm quality related to the disease. We investigated sperm quality and factors determining it in untreated patients with early stage Hodgkin's lymphoma. Design and MethodsOf 2362 males who participated in EORTC H6-H9 trials, 474 (20%) had data available. Sperm quality was defined according to World Health Organization guidelines. Determining factors were studied by logistic regression analysis. ResultsThe median sperm concentration was 40×10 6 /mL (range, 0-345×10 6 /mL) and the median motility 50% (range, 0-90%). Sperm quality was good (concentration ≥20×10 6 /mL and motility ≥50%), intermediate (concentration ≥5×10 6 /mL) and poor (concentration <5×10 6 /mL but >0) in 41%, 49% and 7% of patients, respectively. Three percent of the patients were azoospermic. No relation was found between sperm quality and age or clinical stage of the Hodgkin's lymphoma, but B-symptoms and elevated erythrocyte sedimentation rate predicted poor sperm quality. The odds ratios for the association of poor sperm quality with the variables examined were: presence of B-symptoms, 2.77 (95% CI, 1.50-5.12; p=0.001); erythrocyte sedimentation rate of 50 mm/h or greater, 2.35 (95% CI, 1. p=0.009); fever, 3.22 (95% CI, p=0.005), and night sweats, 3.78 (95% CI, 1.97-7.26; p<0.001). There was no relation between sperm quality and pre-treatment follicle stimulating hormone level. ConclusionsIn this large study of males with Hodgkin's lymphoma, 90% had good or intermediate sperm quality. Three percent were azoospermic. There was an association between sperm quality and the presence or absence of B-symptoms, in particular fever and night sweats. With modern fertilization techniques, in most patients with early-stage Hodgkin's lymphoma sperm quality before treatment is good enough for future fatherhood.Key words: Hodgkin's lymphoma, fertility, male, sperm quality, sperm. Citation: van der

show abstract

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

Cited by 189 publications

References 40 publications

High numbers of active caspase 3–positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome

High numbers of active caspase 3–positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials

Contact Info

Product

Resources

About